Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B0QS
|
|||
| Former ID |
DNC004762
|
|||
| Drug Name |
2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one
|
|||
| Synonyms |
CHEMBL367141; 2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H17NO3
|
|||
| Canonical SMILES |
C1CN(CCOC1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
|
|||
| InChI |
1S/C18H17NO3/c20-16-12-17(19-8-3-10-21-11-9-19)22-18-14-5-2-1-4-13(14)6-7-15(16)18/h1-2,4-7,12H,3,8-11H2
|
|||
| InChIKey |
NVGTWFCMXLHRJF-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA-dependent protein kinase catalytic (PRKDC) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Non-homologous end-joining | |||
| Cell cycle | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| Pathway Interaction Database | DNA-PK pathway in nonhomologous end joining | |||
| Coregulation of Androgen receptor activity | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| BARD1 signaling events | ||||
| Reactome | Nonhomologous End-Joining (NHEJ) | |||
| WikiPathways | DNA Damage Response | |||
| Non-homologous end joining | ||||
| FAS pathway and Stress induction of HSP regulation | ||||
| Cytosolic sensors of pathogen-associated DNA | ||||
| Retinoblastoma (RB) in Cancer | ||||
| Prostate Cancer | ||||
| Double-Strand Break Repair | ||||
| Cell Cycle | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.